State Board of Administration of Florida Retirement System Makes New Investment in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

State Board of Administration of Florida Retirement System bought a new position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNXGet Rating) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 17,038 shares of the company’s stock, valued at approximately $318,000.

Other institutional investors have also recently made changes to their positions in the company. Group One Trading L.P. lifted its position in shares of Crinetics Pharmaceuticals by 31.6% during the first quarter. Group One Trading L.P. now owns 7,318 shares of the company’s stock worth $161,000 after acquiring an additional 1,759 shares in the last quarter. Dupont Capital Management Corp lifted its position in shares of Crinetics Pharmaceuticals by 36.3% during the second quarter. Dupont Capital Management Corp now owns 8,629 shares of the company’s stock worth $161,000 after acquiring an additional 2,297 shares in the last quarter. PDT Partners LLC purchased a new stake in shares of Crinetics Pharmaceuticals during the first quarter worth $220,000. Arizona State Retirement System purchased a new stake in shares of Crinetics Pharmaceuticals during the second quarter worth $188,000. Finally, DekaBank Deutsche Girozentrale lifted its position in shares of Crinetics Pharmaceuticals by 9.7% during the first quarter. DekaBank Deutsche Girozentrale now owns 11,300 shares of the company’s stock worth $215,000 after acquiring an additional 1,000 shares in the last quarter. Hedge funds and other institutional investors own 94.42% of the company’s stock.

Insider Transactions at Crinetics Pharmaceuticals

In other news, insider Stephen F. Betz sold 3,126 shares of the company’s stock in a transaction on Tuesday, November 15th. The shares were sold at an average price of $18.72, for a total value of $58,518.72. Following the transaction, the insider now owns 88,094 shares of the company’s stock, valued at $1,649,119.68. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, insider Stephen F. Betz sold 3,126 shares of the company’s stock in a transaction on Tuesday, November 15th. The shares were sold at an average price of $18.72, for a total value of $58,518.72. Following the transaction, the insider now owns 88,094 shares of the company’s stock, valued at $1,649,119.68. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Stephen F. Betz sold 4,168 shares of the company’s stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $21.01, for a total transaction of $87,569.68. Following the completion of the transaction, the insider now directly owns 100,598 shares in the company, valued at approximately $2,113,563.98. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 14,588 shares of company stock valued at $284,789. 5.90% of the stock is currently owned by company insiders.

Crinetics Pharmaceuticals Price Performance

NASDAQ:CRNX opened at $17.83 on Monday. The company has a market cap of $958.42 million, a P/E ratio of -5.94 and a beta of 1.03. The stock’s fifty day moving average price is $18.53 and its two-hundred day moving average price is $19.21. Crinetics Pharmaceuticals, Inc. has a 1 year low of $15.91 and a 1 year high of $28.95.

Crinetics Pharmaceuticals Profile

(Get Rating)

Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).

See Also

Want to see what other hedge funds are holding CRNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNXGet Rating).

Institutional Ownership by Quarter for Crinetics Pharmaceuticals (NASDAQ:CRNX)

Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.